1-7 of 7
Maria Paz Queipo de LLano, MD
Close
Sort by
Journal Articles

Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012)

Alex Bataller, MD, Ana Garrido, MD, Francesca Guijarro, MD, Marina Diaz-Beyá, MD, Guadalupe Oñate, MD, Montserrat Hoyos, Montserrat Arnan, MD, Mar Tormo, MD, Susana Vives, MD, Maria Paz Queipo De Llano, MD, Olga Salamero, MD, Rosa Coll, MD, David Gallardo, MD, Ferran Vall-Llovera, MD, Lourdes Escoda, MD, Antonia Sampol, MD, Antonio Garcia-Guiñon, MD, Brayan Merchan, MD, Joan Bargay, MD, Monica Lopez-Guerra, PhD, Marta Pratcorona, MD, Lurdes Zamora, PhD, Salut Brunet, MD, Josep F Nomdedeu, MD, Jorge Sierra, MD, Jordi Esteve
Journal: Blood
Blood (2020) 136 (Supplement 1): 31–32.
https://doi.org/10.1182/blood-2020-140670
Published: 2020
Journal Articles

Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival

Ana Garrido, Montserrat Hoyos, Marina Diaz-Beyá, MD, Montserrat Arnan, MD, Susana Vives, MD, Marisa Calabuig, MD, Olga Salamero, MD, David Gallardo, MD, Maria Paz Queipo De Llano, MD, Lourdes Escoda, MD, Antonia Sampol, MD, Ferran Vall-Llovera, MD, Antonio Garcia-Guiñon, MD, Merchan Brayan, MD, Joan Bargay, MD, J Pio Torres, Xavier Ortin, M Luz Amigo, Jose Maria Moraleda, MD PhD, José F. Falantes, David Valcarcel, Mar Tormo, MD, Josep-Maria Ribera, Salut Brunet, MD, Anna Sureda Balari, MD PhD, Jordi Esteve, Jorge Sierra, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-140680
Published: 2020
Journal Articles

Outcome of Adults with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL) Included in Minimal Residual Disease (MRD)-Oriented Trials

Josep-Maria Ribera, Eduardo Cerello Chapchap, MD, Mireia Morgades, M.Prob.S, Eulàlia Genescà, PhD, Cristina Gil, Irene García-Cadenas, Pere Barba, MD PhD, José González-Campos, MD, Anna Torrent, Teresa Bernal del Castillo, MD PhD, Maria Paz Queipo De Llano, MD, María-Luz Amigo, MD, Mar Tormo, MD, Rosa Coll, MD, Ferran Vall-Llovera, MD, Jordi Ribera, PhD, Maria Jose Sanchez, MD, Beatriz Soria, MD, Antonia Cladera, María Teresa Artola, MD, Antoni Garcia-Guiñon, MD, Alberto Giménez Conca, MD, Lourdes Amador Barciela, MD, Juana Ciudad, PhD, Alberto Orfao, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 6–7.
https://doi.org/10.1182/blood-2020-137383
Published: 2020
Journal Articles

Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease

Jorge Sierra, MD, Ana Garrido, Marina Diaz Beya, MD, Montserrat Hoyos, Marisa Calabuig, MD, Susana Vives, MD, Montserrat Arnan Sangerman, MD PhD, Maria Paz Queipo De Llano, MD, Olga Salamero, MD, Ferran Vall-Llovera, MD, Alex Bataller, Francisca Guijarro, MD, Lourdes Escoda, MD, Antonio Garcia-Guiñon, MD, Brayan Merchan, MD MSc, Xavier Ortin, Isabel Sanchez Ortega, MD PhD, Marta Pratcorona, MD PhD, Joan Bargay, MD PhD, Antonia Sampol, Josep Nomdedeu, MD PhD, David Gallardo, Josep-Maria Ribera, MD PhD, Mar Tormo, Jordi Esteve, Salut Brunet, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 289.
https://doi.org/10.1182/blood-2019-128682
Published: 2019
Journal Articles

Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with D e Novo Mutated NPM1 (NPM1mut) a cute Myeloid Leukemia

Guadalupe Oñate, MD, Ana Garrido, MD, Jordi Esteve, MD PhD, Rosa Coll, MD, Montserrat Arnan Sangerman, MD, Susana Vives, MD, Antonia Sampol, MD PhD, Mar Tormo, MD PhD, Lourdes Escoda, MD, Maria Paz Queipo De Llano, MD, Antoni Garcia-Guiñon, MD, Joan Bargay, MD PhD, Olga Salamero, MD, Alba Aljarilla, Salut Brunet, MD PhD, Jorge Sierra, MD, Josep Nomdedeu, MD PhD, Marta Pratcorona, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1492.
https://doi.org/10.1182/blood-2018-99-115337
Published: 2018
Journal Articles

Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).

Alvaro Urbano-Ispizua, MD, Salut Brunet, MD, Mariano Monzo, MD, PhD, Granada Perea, MD, Alfons Navarro, PhD, Jordi Esteve, MD, Juan Berlanga, MD, Josep-Maria Ribera, MD, Javier Bueno, MD, Andreu Llorente, MD, Juan Besalduch, MD, Ramon Guardia, MD, Mar Tormo, MD, Carmen Pedro, MD, Juan-Maria Sanchez, MD, Pio Torres, MD, Maria-Paz Queipo de Llano, MD, Llorens Font, MD, Jose-Maria Moraleda, MD, Josep-Maria Marti, MD, Pilar Vivancos, MD, Maria-Jesus Peñarubia, MD, Josep Nomdedeu, MD, Emili Montserrat, MD, Jorge Sierra, MD
Journal: Blood
Blood (2004) 104 (11): 398.
https://doi.org/10.1182/blood.V104.11.398.398
Published: 2004
Journal Articles

Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC).

Granada Perea, MD, Adriana Lasa, PhD, Anna Aventin, MD, Alicia Domingo, MD, Neus Villamor, MD, Maria Paz Queipo de LLano, MD, Andreu Llorente, MD, Jordi Junca, MD, Carlos Palacios, MD, Cristalina Fernandez, MD, Miquel Guallart, MD, Llorens Font, MD, Mar Tormo, MD, Lourdes Florensa, MD, Joan Bargay, MD, Josep M. Marti, MD, Pilar Vivancos, MD, Pio Torres, MD, Juan Berlanga, MD, Salut Brunet, MD, Jorge Sierra, MD, Josep F. Nomdedeu, MD
Journal: Blood
Blood (2004) 104 (11): 2989.
https://doi.org/10.1182/blood.V104.11.2989.2989
Published: 2004